Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan
about
Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicityIsolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters.Isolated limb perfusion for melanoma.Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies.Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for regional toxicity.Current status of hyperthermic limb perfusion for in-transit melanoma.Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI.Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas.TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome.Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity.Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity.Clinical characteristics of critically ill cancer patients who are undergoing isolated limb perfusion.
P2860
Q33183585-FAC649F8-A7C9-4A00-A5F2-AEC3C1162D76Q33309291-2E96AF8F-2B66-450C-B5E2-9F26BB032FC3Q33561919-3DA06CC8-7BDB-4C1C-A0CC-CD1154E9E934Q34580517-BD1DDE6B-E80D-4D90-8CB5-0343ED404C74Q35646297-5937ECF7-31C1-46B7-A2DB-733F42406237Q35813429-76469D05-EF7D-4371-8A39-23FC9BA9D372Q37130240-08B3D061-5139-45D2-A79D-0ECFE4AB16C9Q37130246-3333E651-E1A9-4743-90B3-2903B1F6E3A8Q43376660-57D4BDD4-4DA1-40AC-A0DF-AA239C7A15BEQ44113644-2404FAA7-1D61-4662-8017-B14A8B7662DCQ45888026-5DCF1819-860D-491F-80DB-F48FFA77CDF6Q46894623-46431702-0DD2-4835-BC3A-30A2521BD734Q47093469-36A0A207-DC63-4CFC-B16A-BC1275E4BF39
P2860
Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Absence of severe systemic tox ...... sis factor-alpha and melphalan
@ast
Absence of severe systemic tox ...... sis factor-alpha and melphalan
@en
Absence of severe systemic tox ...... sis factor-alpha and melphalan
@nl
type
label
Absence of severe systemic tox ...... sis factor-alpha and melphalan
@ast
Absence of severe systemic tox ...... sis factor-alpha and melphalan
@en
Absence of severe systemic tox ...... sis factor-alpha and melphalan
@nl
prefLabel
Absence of severe systemic tox ...... sis factor-alpha and melphalan
@ast
Absence of severe systemic tox ...... sis factor-alpha and melphalan
@en
Absence of severe systemic tox ...... sis factor-alpha and melphalan
@nl
P2093
P1476
Absence of severe systemic tox ...... sis factor-alpha and melphalan
@en
P2093
A C Ogilvie
A M Eggermont
A N van Geel
B C Vrouenraets
O E Nieweg
P2888
P304
P356
10.1007/S10434-999-0405-9
P407
P577
1999-06-01T00:00:00Z